The world’s first malaria vaccine would soon be tested in three African countries – Kenya, Malawi and Ghana.
The vaccine, known as the ‘RTS S’, has been developed by the World Health Organisation and has passed all needed trials.
The test run, in the chosen three nations, is too see how the vaccine would work in the ‘real world’ – especially due to the perceived cumbersome nature of its application.
The vaccine has to be given out once a month for three months, plus one last dose to be taken 18 months later. It’s debatable how parents in the poorest parts of the world would commit to such a course.
The safety and effectiveness of the vaccine would also be monitored by WHO throughout this test run.
According to the BBC: “The pilot will involve more than 750,000 children aged between five and 17 months. Around half will get the vaccine in order to compare the jab’s real-world effectiveness.” the BBC reports.
“In this age group, the four doses have been shown to prevent nearly four in ten cases of malaria.
“This is much lower than approved vaccines for other conditions.
“It also cuts the most severe cases by a third and reduces the number of children needing hospital treatment or blood transfusions.”